{
    "nctId": "NCT02253459",
    "briefTitle": "Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer",
    "officialTitle": "Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 405,
    "primaryOutcomeMeasure": "Progresssion free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer,or lacking standard therapy or being failed to or recurrent after standard therapy;\n2. Patients who have previously treated with \u22644 chemotherapeutic regimes;\n3. Patients who have previously treated with an anthracyclin antibiotics and a taxane;\n4. Age 18 -70 years old, ECOG performance status of 0-2; Life expectancy of 3 months or more;\n5. Patients with at least 1 measurable target lesion determined by CT within 2 weeks prior to enrollment;\n6. Neuropathy \\<CTC2 degree \uff08NCI CTC4.03\uff09within 4 weeks prior to enrollment;\n7. Basically normal results from routine blood test within 1 week prior to enrollment;\n8. Basically normal liver and renal functions within 1 week prior to enrollment;\n9. No abnormal function for major internal organs, no heart diseases.\n\nExclusion Criteria:\n\n1. Received chemotherapy, radiotherapy, therapies with hormones or molecularly targeted drugs 4 weeks prior to enrollment, or received other chemotherapies while participating in this trial;\n2. Patients with documented hypersensitivity to Cremophor EL, or patients with previous taxane treatment related SAE;\n3. Patients of pregnancy or breast feeding;\n4. Patients with previous standard capecitabine treatment ineffective, or patients received standard capecitabine treatment effective, but with less than 6 months of capecitabine clearance period;\n5. Patients with uncontrolled brain metastasis or bone metastasis, which plan for recent surgery or local radiotherapy, or other emergency treatment;\n6. Patients combined with severe and /or uncontrolled medical conditions, including severe cardiovascular disease, uncontrolled diabetes and high blood pressure, severe infection, severe gastrointestinal ulceration, and patients with incontrollable psychiatric history;\n7. Patients with poor compliance;\n8. Patients not fitted for this study determined by the investigators.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}